Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer

NCT01116648 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01116648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01116648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 14, 2010
Completion date
June 1, 2027
Enrollment
155 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, ovarian endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian serous adenocarcinoma, ovarian serous surface papillary adenocarcinoma, primary peritoneal serous adenocarcinoma, triple-negative breast carcinoma